Strong 🏋️♀️
Q3fy21/20 in cr
Rev 361/317
PAT 37.2/20
EPS 1.52/0.83
9mnth fy21/20
Rev 1014/878
PAT 87.8 /53.1
EPS 3.24/2.18
API Business up 17.2%
Formulations 15.0%
Alivira award best Company in AH India/ME/Africa
Formulations
EU subdued due operational challenges of Covid
Spain & Germany impacted while Benelux & Sweden reported strong growth
Growth to accelerate with recent launches of CitramoxLA & Halofusol. Tulathromycin launch to reflect from the current quarter
Brazil & Turkey grow strongly driven by mkt share gain existing portfolio & new launches
India business doubled last 9 months
Integration Zoetis portfolio completed
API Business
Highest quarterly sales 1,297Mn, growth 20%
1/3rd sales from global Top-10 AH players in 9M
Best Ever Quarterly Revenue, EBITDA & PAT
Rev 4,350 mn, up 24% yoy & 8% qoq Q3’21 EBITDA 1,085 Mn, up 32% yoy & 8% qoq
PAT 658 Mn, up 59% yoy & 16% qoq
Basic EPS 18.47
API Business
Regulated mkt rev 3110 mn, up 12% yoy
,contributed 72% of Q3’21 rev, decline from Q2 result of robust growth in other mkts
Other mkts rev 1240 mn, up 71% yoy
Rev growth 24% yoy (37% yoy ex-ranitidine) driven by growth in vol, scale up Vizag
New products 9% Q3’21rev
CRAMS
Tracking well to plan ,addition of new customers, solid growth order book
R&D & Ops
Vizag onstream, commercialized as planned in Q3
Filed 3 new DMFs US mkt ,2 EU mkt during Q3’21
Market extensions 6 of existing products across 7 different geographies
R&D 138 mn 3.2% Rev
Highest ever cons quarterly rev 26518 cr, up 24.2% yoy
India business highest ever quarterly rev 19,007 cr, up 25.1% yoy
Mobile services India rev up 32.4% yoy led by improving realizations,strong customer addn
Airtel Business rev up by 9.2% yoy back of strong demand for connectivity and solutions
Digital TV business strengthened leadership position
Cons EBITDA 12178 cr
EBITDA margin at 45.9%, up 464 bps yoy
India business EBITDA 8,589 cr EBITDA margin 45.2%; up 594 bps YoY
Cons EBIT 4665 cr ,EBIT margin 17.6%
India EBIT margin 12.7%
Cons Net income (after exp items) 854 cr
Industry leading operational indicators, strong business momentum 4G customers up 12.9 mn for Q3 to 165.6 mn
Mobile ARPU 166 vs 135 Q3’20
Rural demand remained strong, urban showed pickup
Healthcare portfolio showed good response due to covid
Product penetration of 4% for Boroplus,Balms,Kesh king,etc
Double digit vol growth guidance for Q4
Manag confident of new launches Boroplus,Emasol
Honey controversy appears to settle down, mkt changing from seasonal to perennial
Fair & Handsome sales showing uptick post rebranding, relaunch
Sanitiser sales witnessing slowdown
Hair oils seeing demand in domestic & ME mkts
Q3 sales Zandu segment
Honey up 2.5% ,Chyawanprash 24%
International business up 26% yoy led by growth in ME & SAARC ,new launches contributed 4% to sales in Q3 ,creme21 grew 82%
30+ new product launches Fy21
E comm sales up 3.5x in Q3 ,up 210 bps
MT channel growth 51% in Q3
Generic FDF
ARV,Anti-DM,CVS,PPIs,Onco
Filed 26 ANDAs with USFDA
9 final & 8 tentative approvals
Filed 12 dossiers in Canada, 9 in EU ,8 with WHO,2 in S.Africa, 2 in India
Laurus Synthesis
CDMO services for Global pharma
Steroids,hormone mftg
Speciality ingredients in Nutraceuticals,dietary,cosmetics
Commercial scale mfg,clinical phase supplies,Analytics & research
API validation plannd in Unit 5
Optalmic initiated
LSPL-API validatn planned
Q3Fy21 Highlights Revenue from ops up 20% yoy driven by 4 new launches in Q3 & increase in mkt share existing products across the three segments – API, PFI and FD
EBITDA up 29.7% yoy, +190 bps margin expansion yoy on changing product mix with higher contribution from FD and PFI , improved operational efficiencies from higher capacity utilization
PAT 147 cr up 129.4% yoy
Net Debt down 22% yoy
Net debt to EBITDA 0.7x vs. 1.4x as of Q3fy20
ROCE 32.4%, up on account of higher capacity utilization via addition of new modules & equipment with limited capital expenditure
Q3fy21 launched Ramelteon, Dexmethylphenidate HCI and Potassium Chloride ER tablets (Klor-Con), from GPI and Guaifenesin ER tablets from GIL